Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Argos Therapeutics Identifier:
First received: April 19, 2012
Last updated: July 17, 2015
Last verified: July 2015
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone.

Condition Intervention Phase
Advanced Renal Cell Carcinoma
Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Drug: Standard Treatment
Biological: AGS-003
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Resource links provided by NLM:

Further study details as provided by Argos Therapeutics:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: From date of subject randomization to date of death; assessed up to 42 months or until 290 deaths have been accrued on study ] [ Designated as safety issue: No ]
    Duration from randomization to death

Secondary Outcome Measures:
  • Progression Free Survival [ Time Frame: From date of subject randomization to date of progression; assessed up to 42 months ] [ Designated as safety issue: No ]
  • Tumor Response [ Time Frame: From date of subject randomization to date of progression; assessed up to 42 months ] [ Designated as safety issue: No ]
    Monitor for evidence of the following tumor responses: Objective response rate, Duration of overall response, and Disease control rate.

  • Monitor treatment emergent adverse events between both arms [ Time Frame: From safety baseline until either meeting a discontinuation criterion or death; assessed up to 42 months ] [ Designated as safety issue: Yes ]
    Compare adverse events between both arms.

Estimated Enrollment: 450
Study Start Date: November 2012
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AGS-003 + Standard Treatment
Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
Biological: AGS-003
Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
Active Comparator: Standard Treatment
Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
Drug: Standard Treatment
Standard treatment for Renal Cell Carcinoma
Other Name: Sunitinib


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Key Inclusion Criteria for Tumor Collection:

  1. Diagnosis or clinical signs of advanced RCC
  2. Scheduled for cytoreductive or partial nephrectomy

Key Exclusion Criteria for Tumor Collection:

  1. Known inability to undergo sunitinib treatment as currently labeled, due to pre-existing medical conditions
  2. Requirement for systemic chronic immunosuppressive drugs or corticosteroids
  3. Evidence of brain metastases prior to nephrectomy

Key Inclusion Criteria for Treatment Study:

  1. Advanced disease, histologically assessed as RCC, with predominantly clear cell histology
  2. Metastatic disease (measurable or non-measurable) that can be monitored throughout the course of the study participation per RECIST 1.1
  3. Subjects who are candidates for standard first-line therapy initiating with sunitinib
  4. Time from diagnosis to treatment < 1 year
  5. Karnofsky performance status (KPS) ≥ 70%
  6. Life expectancy of 6 months or greater
  7. Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade ≤ 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
  8. Adequate hematologic, renal, hepatic, and coagulation function
  9. Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug
  10. Normal ECG or clinically non-significant finding(s) at Screening
  11. Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study
  12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Key Exclusion Criteria for Treatment Study:

  1. Prior systemic therapy (including adjuvant or neoadjuvant) of any kind for RCC, including immunotherapy, chemotherapy, hormonal, or investigational therapy
  2. Prior history of malignancy within the preceding 3 years, except for adequately treated in situ carcinomas or non-melanoma skin cancer, adequately treated early stage breast cancer, superficial bladder cancer, and non-metastatic prostate cancer with a normal PSA
  3. History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease
  4. Patients with 4 or more of the following risk factors:

    1. Hgb < LLN
    2. Corrected calcium > 10.0 mg/dL
    3. KPS < 80%
    4. Neutrophils > ULN
    5. Platelets > ULN
  5. Planned or elective surgical treatment post-nephrectomy for the direct management of RCC, within 28 days before Visit 1 (Week 0)
  6. NCI CTCAE Grade 3 hemorrhage < 28 days before Visit 1 (Day 0)
  7. Clinically significant cardiovascular conditions within 3 months prior to Randomization
  8. Significant gastrointestinal abnormalities
  9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
  10. Active autoimmune disease or condition requiring chronic immunosuppressive therapy
  11. Clinically significant infections, including human immunodeficiency virus, syphilis, and active hepatitis B or C
  12. Current treatment with an investigational therapy on another clinical trial
  13. Pregnancy or breastfeeding
  14. Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01582672

  Hide Study Locations
United States, Arizona
Scottsdale, Arizona, United States, 85259
United States, Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
La Jolla, California, United States, 92093
Los Angeles, California, United States, 90024
Los Angeles, California, United States, 90048
San Francisco, California, United States, 94115
United States, Colorado
Aurora, Colorado, United States, 80045
Colorado Springs, Colorado, United States, 80909
Denver, Colorado, United States, 80211
United States, Florida
Miami, Florida, United States, 33140
Tampa, Florida, United States, 33612
United States, Georgia
Atlanta, Georgia, United States, 30322
Augusta, Georgia, United States, 30912
Marietta, Georgia, United States, 30060
United States, Idaho
Boise, Idaho, United States, 83706
Meridian, Idaho, United States, 83642
United States, Illinois
Chicago, Illinois, United States, 60612
Maywood, Illinois, United States, 60153
Springfield, Illinois, United States, 62702
United States, Indiana
Greenwood, Indiana, United States, 46143
Indianapolis, Indiana, United States, 46202
Indianapolis, Indiana, United States, 46237
United States, Iowa
Iowa City, Iowa, United States, 52242
United States, Kansas
Kansas City, Kansas, United States, 66160
Wichita, Kansas, United States, 67226
United States, Louisiana
Metairie, Louisiana, United States, 70006
New Orleans, Louisiana, United States, 70112
New Orleans, Louisiana, United States, 70121
United States, Maryland
Baltimore, Maryland, United States, 21201
Baltimore, Maryland, United States, 21204
United States, Massachusetts
Boston, Massachusetts, United States, 02114
Burlington, Massachusetts, United States, 01805
United States, Michigan
Detroit, Michigan, United States, 48201
Detroit, Michigan, United States, 48202
Grand Rapids, Michigan, United States, 49503
Lansing, Michigan, United States, 48912
United States, Minnesota
Minneapolis, Minnesota, United States, 55455
Rochester, Minnesota, United States, 55905
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, Nebraska
Omaha, Nebraska, United States, 68114
Omaha, Nebraska, United States, 68130
Omaha, Nebraska, United States, 68198
United States, New Hampshire
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Hackensack, New Jersey, United States, 07601
United States, New Mexico
Albuquerque, New Mexico, United States, 87131
United States, New York
Albany, New York, United States, 12208
East Syracuse, New York, United States, 13057
New Hyde Park, New York, United States, 11040
New York, New York, United States, 10016
New York, New York, United States, 10029
Stony Brook, New York, United States, 11794
Syracuse, New York, United States, 13210
United States, North Carolina
Charlotte, North Carolina, United States, 28204
Durham, North Carolina, United States, 27710
Raleigh, North Carolina, United States, 27607
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Cincinnati, Ohio, United States, 45212
Middletown, Ohio, United States, 45042
Toledo, Ohio, United States, 43623
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Portland, Oregon, United States, 97213
Portland, Oregon, United States, 97239
Springfield, Oregon, United States, 97477
United States, Pennsylvania
Allentown, Pennsylvania, United States, 18103
Danville, Pennsylvania, United States, 17822
Easton, Pennsylvania, United States, 18045
Hershey, Pennsylvania, United States, 17033
Philadelphia, Pennsylvania, United States, 19111
Philadelphia, Pennsylvania, United States, 19140
Pittsburgh, Pennsylvania, United States, 15232
Pittsburgh, Pennsylvania, United States, 15212
United States, Rhode Island
Providence, Rhode Island, United States, 02906
United States, South Carolina
Charleston, South Carolina, United States, 29425
Greenville, South Carolina, United States, 29605
Myrtle Beach, South Carolina, United States, 29572
United States, South Dakota
Sioux Falls, South Dakota, United States, 57105
United States, Tennessee
Nashville, Tennessee, United States, 37215
United States, Texas
Dallas, Texas, United States, 75231
Houston, Texas, United States, 77030
San Antonio, Texas, United States, 78240
San Antonio, Texas, United States, 78229
United States, Utah
Salt Lake City, Utah, United States, 84132
United States, Virginia
Charlottesville, Virginia, United States, 22908
Virginia Beach, Virginia, United States, 23462
United States, Washington
Seattle, Washington, United States, 98101
Seattle, Washington, United States, 98109
United States, Wisconsin
Milwaukee, Wisconsin, United States, 53226
Milwaulkee, Wisconsin, United States, 53215
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Ontario
Hamilton, Ontario, Canada, L8N4A6
London, Ontario, Canada, N6A5W9
Oshawa, Ontario, Canada, L1G 2B9
Ottawa, Ontario, Canada, K1H8L6
Canada, Quebec
Greenfield Park, Quebec, Canada, J4V2HI
Montreal, Quebec, Canada, H2L4M1
Montreal, Quebec, Canada, H3T1E2
Quebec, Canada, G1R3S1
Czech Republic
Hradec Kralove, Czech Republic, 50005
Liberec, Czech Republic, 46063
Olomouc, Czech Republic, 77520
Prague, Czech Republic, 10034
Praha 8, Czech Republic, 18081
Budapest, Hungary, H-1062
Budapest, Hungary, H-1122
Debrecen, Hungary, H-4032
Haifa, Israel, 31096
Jerusalem, Israel, 91120
Kfar Saba, Israel, 44281
Rehovot, Israel, 76100
Tel Hashomer, Israel, 52621
Zerifin, Israel, 70300
Roma, Italy, 00152
Rome, Italy, 00144
Badalona, Spain, 08916
Barcelona, Spain, 08003
Barcelona, Spain, 08035
Madrid, Spain, 28033
Madrid, Spain, 28050
Madrid, Spain, 28046
Sevilla, Spain, 41013
Valencia, Spain, 46009
Vigo, Spain, 36204
United Kingdom
Cambridge, United Kingdom, CB20QQ
Norwich, United Kingdom, NR47UY
Preston, United Kingdom, PR29HT
Sponsors and Collaborators
Argos Therapeutics
Principal Investigator: Robert Figlin, MD, FACP Cedars-Sinai Medical Center
Principal Investigator: Christopher G Wood, MD, FACP M.D. Anderson Cancer Center
  More Information

No publications provided

Responsible Party: Argos Therapeutics Identifier: NCT01582672     History of Changes
Other Study ID Numbers: AGS-003-007, 2012-000871-17
Study First Received: April 19, 2012
Last Updated: July 17, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Argos Therapeutics:
Kidney Cancer

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Diseases
Kidney Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms processed this record on December 01, 2015